UB Paderborn / Katalog / Suche / in CDI

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The lancet oncology, 2017-01, Vol.18 (1), p.31-41

2017

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2980-2987

2016

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

The lancet oncology, 2011-08, Vol.12 (8), p.815-824

2011

Link zum Volltext

Verfügbarkeit prüfen

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1143-1169

2018

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2969-2979

2016

Link zum Volltext

Verfügbarkeit prüfen

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1061-1069

2013

Link zum Volltext

Verfügbarkeit prüfen

Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers

Journal of clinical oncology, 2006-06, Vol.24 (17), p.2673-2678

2006

Link zum Volltext

Verfügbarkeit prüfen

Towards evidence-based response criteria for cancer immunotherapy

Nature communications, 2023-05, Vol.14 (1), p.3001-3001

2023

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1363-1372

2018

Link zum Volltext

Verfügbarkeit prüfen

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeted therapy in BRAF -mutated lung adenocarcinoma

The lancet oncology, 2016-05, Vol.17 (5), p.550-551

Laurie, Scott A

2016

Link zum Volltext

Verfügbarkeit prüfen

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Nature communications, 2022-06, Vol.13 (1), p.3607-3607, Article 3607

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

The Lancet (British edition), 2023-12, Vol.402 (10419), p.2295-2306

2023

Link zum Volltext

Verfügbarkeit prüfen

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Nature medicine, 2023-10, Vol.29 (10), p.2559-2569

2023

Link zum Volltext

Verfügbarkeit prüfen

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Cancer discovery, 2023-08, Vol.13 (8), p.1802

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Journal of clinical oncology, 2010-01, Vol.28 (1), p.49-55

2010

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre

International journal of radiation oncology, biology, physics, 2018-08, Vol.101 (5), p.1133-1140

2018

Link zum Volltext

Verfügbarkeit prüfen

American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

Journal of clinical oncology, 2006-08, Vol.24 (22), p.3693-3704

2006

Link zum Volltext

Verfügbarkeit prüfen

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-01, Vol.27 (3), p.404-410

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

Journal of clinical oncology, 2009-05, Vol.27 (13), p.2253-2260

2009

Link zum Volltext

Verfügbarkeit prüfen

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.434-445

2022

Link zum Volltext

Verfügbarkeit prüfen

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not

Lung cancer (Amsterdam, Netherlands), 2016-07, Vol.97, p.15-21

2016

Link zum Volltext

Verfügbarkeit prüfen

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck

Cancer treatment reviews, 2017-03, Vol.54, p.43-57

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers

Towards evidence-based response criteria for cancer immunotherapy

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Targeted therapy in BRAF -mutated lung adenocarcinoma

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre

American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck

Suchergebnisse filtern